Evercore ISI reiterates outperform rating on IBM stock amid sector data

Evercore ISI maintains its outperform rating on IBM with a $315 price target, following Accenture's Q3 results which beat expectations with 7% year-over-year revenue growth at constant currency; however, Accenture's bookings declined 7%, potentially impacting IBM's consulting signings. Despite this, IBM is projected to have FY2025 EPS of $11.42, and analysts at BofA Securities and Stifel have reiterated Buy ratings, citing IBM's strong free cash flow, AI initiatives, and hybrid-cloud capabilities, while UBS maintains a Sell rating.

Analysis

Despite a maintained Outperform rating and a $315 price target from Evercore ISI, IBM faces potential near-term headwinds highlighted by competitor Accenture's recent earnings report. While Accenture beat revenue and EPS estimates with 7% year-over-year constant currency growth, its bookings declined 7% YoY, signaling a potential slowdown in consulting demand. This is a notable concern for IBM, whose own consulting signings already fell 9% YoY in the first quarter. IBM's management has preemptively addressed this by guiding for an approximately flat performance in its consulting business for calendar year 2025, factoring in macroeconomic and federal spending pressures. The market sentiment on IBM is sharply divided; bullish analysts from BofA Securities (PT $320) and Stifel (PT $290) emphasize strong free cash flow and long-term growth from AI and hybrid-cloud initiatives, while UBS maintains a Sell rating with a $170 target. This divergence occurs as IBM's stock trades near its 52-week high after a 67.77% annual gain, with analysis suggesting it may be trading above its intrinsic fair value, balancing long-term strategic developments like quantum computing against immediate sectoral challenges.

Key Decisions for Investors

• Investors should weigh the bullish long-term narrative around AI, hybrid-cloud, and quantum computing against the immediate headwind in the consulting segment, as indicated by Accenture's 7% bookings decline.
• Monitor IBM's upcoming Q2 earnings report closely, with a specific focus on consulting signings and the book-to-bill ratio to validate whether the weakness seen at Accenture is impacting IBM's performance.
• Given the stock's significant 67.77% appreciation over the past year and a valuation potentially above fair value, consider whether the positive outlook is fully priced in, leaving the stock vulnerable to near-term guidance adjustments.
• Acknowledge the high degree of uncertainty reflected in the wide dispersion of analyst price targets, ranging from UBS's $170 to BofA's $320, which warrants a careful assessment of risk-reward before initiating or adjusting a position.